Cemdisiran Withdrawn Phase 2 Trials for Atypical Hemolytic Uremic Syndrome (aHUS) Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Withdrawn | Treatment | 2 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT03999840 | Eculizumab to Cemdisiran Switch in aHUS | |
| NCT03303313 | A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome |